NCT04701333View on ClinicalTrials.gov

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

June 24, 2022

Study Completion Date

March 1, 2023

Conditions
Lactation Suppressed
Interventions
DRUG

Cabergoline 1 MG

Dopamine agonist

DRUG

Placebo

Placebo

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04701333 - Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss | Biotech Hunter | Biotech Hunter